The Company is into manufacturing of agrochemical active ingredients (technical), bulk and formulations, intermediate products and it sells its products in India as well as exports them to approximately 24 countries.Astec also has undertaken a number of custom synthesis projects, for its clients in Europe, Japan and the US. It is present only in business to business sale (B2B).[1][2][3]
Product PortfolioThe company offers a range of products and intermediates, including fungicides, insecticides, herbicides, and various chemical compounds, serving global customers and including triazole fungicides, heterocyclic herbicides, sulfonylurea herbicides, synthetic pyrethroids, fluorinated compounds, halides, intermediates, ketones, ethers, alcohols, and many others.[1]
| S.No. | Name | Current Price (Rs.) | Price to Earning | Market Capitalization (Rs.Cr.) | Dividend yield (%) | Net Profit latest quarter (Rs.Cr.) | YOY Quarterly profit growth (%) | Sales latest quarter (Rs.Cr.) | YOY Quarterly sales growth (%) | Return on capital employed (%) | Sales (Rs.Cr.) | OPM (%) | Profit after tax (Rs.Cr.) | Profit after tax latest quarter (Rs.Cr.) | Price to book value | Return on assets (%) | Debt to equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. | UPL | 802.95 | 28.54 | 67718.52 | 0.75 | 612.00 | 209.91 | 12019.00 | 8.38 | 7.66 | 47715.00 | 17.15 | 2372.46 | 484.10 | 2.12 | 0.95 | 0.94 |
| 2. | P I Industries | 3283.80 | 32.93 | 49805.99 | 0.49 | 409.30 | -19.46 | 1872.30 | -15.70 | 22.86 | 7460.70 | 27.18 | 1512.50 | 409.30 | 4.60 | 14.46 | 0.02 |
| 3. | Sumitomo Chemi. | 459.65 | 42.38 | 22902.10 | 0.26 | 177.90 | -6.78 | 914.44 | -5.86 | 25.14 | 3249.74 | 20.16 | 540.43 | 177.90 | 7.18 | 13.91 | 0.02 |
| 4. | Bayer Crop Sci. | 4535.90 | 33.47 | 20378.72 | 2.76 | 152.70 | 12.03 | 1553.40 | -10.60 | 24.80 | 5571.80 | 13.37 | 608.90 | 152.70 | 6.53 | 11.56 | 0.03 |
| 5. | Sharda Cropchem | 839.30 | 16.77 | 7575.40 | 1.07 | 74.35 | 75.22 | 929.11 | 19.59 | 16.50 | 4671.78 | 16.40 | 451.81 | 74.31 | 2.83 | 6.84 | 0.00 |
| 6. | Rallis India | 267.15 | 30.42 | 5195.24 | 0.94 | 102.00 | -0.39 | 861.00 | -7.22 | 10.12 | 2770.00 | 11.84 | 170.77 | 97.62 | 2.53 | 4.15 | 0.03 |
| 7. | Dhanuka Agritech | 1112.80 | 17.92 | 5018.53 | 0.18 | 93.97 | -20.04 | 598.25 | -8.56 | 28.29 | 2013.83 | 20.12 | 280.01 | 93.97 | 3.25 | 17.27 | 0.02 |
| 8. | Astec Lifescienc | 687.60 | – | 1532.64 | 0.00 | -24.45 | 36.61 | 73.72 | -25.20 | -12.89 | 378.19 | -4.73 | -114.01 | -24.45 | 3.71 | -14.76 | 0.89 |
| – | Median: 23 Co. | 358.6 | 30.66 | 1977.12 | 0.18 | 19.46 | 4.58 | 456.94 | 5.76 | 13.04 | 1374.5 | 11.41 | 39.66 | 19.21 | 2.53 | 5.4 | 0.27 |
Standalone figures in ₹ crores
| Dec 2022 | Dec 2023 | Dec 2024 | Jun 2023 | Jun 2024 | Jun 2025 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 117 | 51 | 94 | 143 | 69 | 91 | 127 | 154 | 120 | 200 | 111 | 99 | 74 |
Expenses | 105 | 69 | 100 | 140 | 116 | 102 | 122 | 141 | 114 | 166 | 114 | 118 | 80 |
Operating Profit | 12 | -18 | -6 | 3 | -46 | -11 | 5 | 13 | 6 | 33 | -3 | -20 | -7 |
Other Income | 4 | 1 | 2 | 2 | 1 | 0 | 3 | 2 | 1 | 4 | 1 | 2 | 1 |
Profit before tax | 1 | -32 | -25 | -11 | -62 | -33 | -6 | -1 | -16 | 25 | -18 | -39 | -24 |
Tax % | 31% | -24% | 60% | -26% | -36% | 0% | -19% | 3% | 3% | 25% | -24% | 0% | 0% |
Net Profit | 1 | -24 | -40 | -8 | -40 | -33 | -5 | -1 | -16 | 18 | -13 | -39 | -24 |
EPS in Rs | 0.37 | -10.87 | -18.04 | -3.67 | -17.74 | -14.76 | -2.23 | -0.44 | -7.19 | 8.17 | -6.00 | -17.22 | -10.97 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 189 | 252 | 221 | 298 | 368 | 431 | 522 | 555 | 677 | 628 | 458 | 381 | 378 |
Expenses | 155 | 200 | 190 | 236 | 299 | 354 | 437 | 443 | 522 | 551 | 464 | 447 | 396 |
Operating Profit | 34 | 52 | 31 | 63 | 69 | 76 | 85 | 112 | 154 | 77 | -6 | -66 | -18 |
Other Income | 0 | -15 | -0 | -8 | 12 | 11 | 12 | 8 | 10 | 13 | 5 | 6 | 4 |
Interest | 9 | 12 | 12 | 12 | 11 | 12 | 13 | 5 | 9 | 21 | 25 | 37 | 40 |
Depreciation | 14 | 12 | 10 | 14 | 15 | 19 | 23 | 26 | 34 | 34 | 36 | 44 | 45 |
Profit before tax | 11 | 12 | 8 | 29 | 56 | 56 | 61 | 89 | 121 | 35 | -62 | -141 | -98 |
Net Profit | 9 | 15 | 0 | 19 | 35 | 36 | 47 | 65 | 90 | 26 | -47 | -135 | -114 |
EPS in Rs | 4.07 | 6.65 | 0.16 | 8.56 | 15.68 | 16.00 | 21.19 | 28.88 | 40.10 | 11.39 | -20.98 | -60.18 | -50.96 |
Dividend Payout % | 22% | 16% | 0% | 15% | 8% | 8% | 6% | 5% | 3% | 12% | 0% | 0% | – |
Standalone figures in ₹ crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 19 | 19 | 19 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 22 |
Reserves | 96 | 117 | 99 | 118 | 150 | 183 | 227 | 289 | 376 | 399 | 349 | 214 | 391 |
Borrowings | 79 | 93 | 127 | 127 | 125 | 176 | 99 | 188 | 280 | 341 | 494 | 555 | 367 |
Other Liabilities | 85 | 128 | 84 | 69 | 119 | 83 | 227 | 182 | 221 | 219 | 111 | 92 | 102 |
Total Liabilities | 279 | 358 | 329 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 974 | 880 | 883 |
Fixed Assets | 130 | 127 | 94 | 103 | 115 | 167 | 194 | 213 | 340 | 318 | 386 | 499 | 500 |
Gross Block | 182.75 | 191.80 | 104.70 | 124.10 | 149.81 | 221.02 | 271.07 | 315.61 | 477.20 | 488.14 | 592.43 | 749.32 | – |
Accumulated Depreciation | 52.70 | 64.57 | 10.36 | 21.49 | 35.05 | 54.38 | 77.39 | 102.94 | 137.32 | 169.79 | 206.65 | 250.79 | – |
CWIP | 6 | 12 | 20 | 8 | 42 | 19 | 24 | 116 | 23 | 127 | 165 | 21 | 0 |
Investments | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Assets | 142 | 217 | 214 | 223 | 256 | 275 | 354 | 349 | 534 | 533 | 423 | 360 | 382 |
Total Assets | 279 | 358 | 329 | 334 | 413 | 461 | 572 | 678 | 897 | 979 | 974 | 880 | 883 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operating Activity | 14 | 3 | 3 | 19 | 65 | 15 | 169 | -8 | 23 | 74 | 10 | -8 |
Cash from Investing Activity | -16 | -14 | -16 | -18 | -49 | -52 | -74 | -73 | -104 | -112 | -135 | -15 |
Cash from Financing Activity | 2 | 11 | 15 | -1 | -18 | 37 | -95 | 81 | 80 | 38 | 125 | 24 |
Net Cash Flow | -0 | -0 | 2 | 1 | -2 | -0 | 0 | 0 | 0 | -0 | 0 | 0 |
Standalone Figures in ₹ Crores / Yearly
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 86 | 143 | 132 | 136 | 122 | 103 | 112 | 123 | 148 | 90 | 135 | 141 |
Inventory Days | 187 | 143 | 186 | 133 | 122 | 121 | 131 | 113 | 176 | 268 | 224 | 196 |
Days Payable | 120 | 181 | 179 | 117 | 156 | 83 | 219 | 137 | 180 | 161 | 102 | 100 |
Cash Conversion Cycle | 153 | 105 | 140 | 152 | 88 | 141 | 24 | 99 | 145 | 197 | 256 | 237 |
Working Capital Days | 30 | 17 | -29 | 0 | -8 | -2 | 8 | 4 | 12 | -17 | -1 | -26 |
ROCE % | 11% | 20% | 10% | 20% | 22% | 20% | 20% | 22% | 22% | 8% | -4% | -13% |
Direct from BSE filings, auto-summarised
External media mentions & references
Editorial & research coverage
Nov 2022
Nov 2022
May 2022
Nov 2021
Aug 2021
Feb 2021
Stock Analysis
Astec Life Sciences Limited is engaged in the manufacturing of agrochemical active ingredients, intermediates, and formulations, operating on a business-to-business model and exporting to approximately 24 countries.
The Chairman cited higher volumes and better gross margins in the Enterprise business for EBITDA improvement in H1 FY26.
Currently no data available for Order Book.
Corporate Announcements
